Poor adherence to entecavir treatment increases the risk of developing adverse liver-related events, including hepatocellular carcinoma, cirrhotic complications and mortality, in patients with chronic hepatitis B, especially among those with liver cirrhosis, as shown in a recent study.
Fungal microbiome, also called the mycobiome, appears to be highly variable in patients with well-characterized fungal diseases, a recent study has shown. Moreover, severe asthmatics have the highest fungal loads, along with those receiving steroid and antifungal therapy.
Hepatitis C virus (HCV) treatment may benefit patients with HCV-related hepatocellular carcinoma (HCC) who respond to the initial HCC palliative treatment, suggest the results of a study, adding, however, that treating HCV in HCC patient undergoing noncurative HCC treatment remains debatable.
Higher doses of rifampin result in more rapid sputum sterilization and similar toxicity, a study has shown. These findings support the investigation of increased rifampin doses to shorten tuberculosis treatment.
Results of a study conducted by the Chinese University of Hong Kong (CUHK) revealed that patients who recovered from hepatitis B virus (HBV) infection are still at risk for hepatocellular carcinoma (HCC).
A US study suggests that expanding HIV screening to reduce undiagnosed infections and increasing access to care and treatment to achieve viral suppression are important to lessen HIV transmission. It is also imperative that prevention methods, such as condoms and pre-exposure prophylaxis, be easily accessed, particularly among young men who have sex with men (MSM) and MSM of colour.
In patients with chronic hepatitis B virus (HBV) infection, tenofovir alafenamide (TAF) shows comparable 96-week efficacy and improved renal and bone safety with tenofovir disoproxil fumarate (TDF), a recent study has shown.